JP7770769B2 - 免疫刺激性オリゴヌクレオチド - Google Patents

免疫刺激性オリゴヌクレオチド

Info

Publication number
JP7770769B2
JP7770769B2 JP2020531982A JP2020531982A JP7770769B2 JP 7770769 B2 JP7770769 B2 JP 7770769B2 JP 2020531982 A JP2020531982 A JP 2020531982A JP 2020531982 A JP2020531982 A JP 2020531982A JP 7770769 B2 JP7770769 B2 JP 7770769B2
Authority
JP
Japan
Prior art keywords
cholesteryl
oligonucleotide
linker
immunostimulatory
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020531982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506246A5 (enExample
JP2021506246A (ja
Inventor
イルグ，トマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco Animal Health GmbH
Original Assignee
Elanco Animal Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Animal Health GmbH filed Critical Elanco Animal Health GmbH
Publication of JP2021506246A publication Critical patent/JP2021506246A/ja
Publication of JP2021506246A5 publication Critical patent/JP2021506246A5/ja
Priority to JP2023128316A priority Critical patent/JP2023153970A/ja
Application granted granted Critical
Publication of JP7770769B2 publication Critical patent/JP7770769B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020531982A 2017-12-15 2018-12-07 免疫刺激性オリゴヌクレオチド Active JP7770769B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023128316A JP2023153970A (ja) 2017-12-15 2023-08-07 免疫刺激性オリゴヌクレオチド

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17207750 2017-12-15
EP17207740 2017-12-15
EP17207750.5 2017-12-15
EP17207746 2017-12-15
EP17207740.6 2017-12-15
EP17207746.3 2017-12-15
PCT/EP2018/084019 WO2019115402A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023128316A Division JP2023153970A (ja) 2017-12-15 2023-08-07 免疫刺激性オリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2021506246A JP2021506246A (ja) 2021-02-22
JP2021506246A5 JP2021506246A5 (enExample) 2022-01-11
JP7770769B2 true JP7770769B2 (ja) 2025-11-17

Family

ID=66818991

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2020531982A Active JP7770769B2 (ja) 2017-12-15 2018-12-07 免疫刺激性オリゴヌクレオチド
JP2020531972A Active JP7273040B2 (ja) 2017-12-15 2018-12-07 免疫刺激性オリゴヌクレオチド
JP2020531988A Active JP7458977B2 (ja) 2017-12-15 2018-12-07 免疫刺激性組成物
JP2023128316A Pending JP2023153970A (ja) 2017-12-15 2023-08-07 免疫刺激性オリゴヌクレオチド
JP2023134080A Active JP7760560B2 (ja) 2017-12-15 2023-08-21 免疫刺激性組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020531972A Active JP7273040B2 (ja) 2017-12-15 2018-12-07 免疫刺激性オリゴヌクレオチド
JP2020531988A Active JP7458977B2 (ja) 2017-12-15 2018-12-07 免疫刺激性組成物
JP2023128316A Pending JP2023153970A (ja) 2017-12-15 2023-08-07 免疫刺激性オリゴヌクレオチド
JP2023134080A Active JP7760560B2 (ja) 2017-12-15 2023-08-21 免疫刺激性組成物

Country Status (24)

Country Link
US (7) US11542507B2 (enExample)
EP (4) EP3701032A1 (enExample)
JP (5) JP7770769B2 (enExample)
KR (4) KR20250048594A (enExample)
CN (5) CN111801116B (enExample)
AU (5) AU2018385257B2 (enExample)
BR (2) BR112020011838A2 (enExample)
CA (3) CA3085657A1 (enExample)
CL (3) CL2020001561A1 (enExample)
CO (3) CO2020007100A2 (enExample)
CR (1) CR20200260A (enExample)
DK (1) DK3700564T3 (enExample)
DO (3) DOP2020000107A (enExample)
ES (1) ES3052969T3 (enExample)
IL (3) IL274975A (enExample)
MX (4) MX2020006244A (enExample)
PE (3) PE20200933A1 (enExample)
PH (3) PH12020550903A1 (enExample)
PL (1) PL3700564T3 (enExample)
SG (3) SG11202004773SA (enExample)
TW (3) TWI911138B (enExample)
UY (3) UY38014A (enExample)
WO (3) WO2019115385A1 (enExample)
ZA (1) ZA202004317B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021154745A1 (en) * 2020-01-27 2021-08-05 Oregon State University Gonorrhea subunit vaccine
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
CN112159814B (zh) * 2020-10-29 2023-05-16 中国农业科学院兰州兽医研究所 一种CpG寡聚脱氧核苷酸及制备与其用途
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN116218852A (zh) * 2023-02-22 2023-06-06 中国人民解放军陆军军医大学 一种靶向基因启动子G-四联体区域的sgRNA及其用途
CN120290549A (zh) * 2024-01-09 2025-07-11 康希诺(上海)生物研发有限公司 一种免疫刺激序列截断多聚a尾的序列构建及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506790A (ja) 2003-09-25 2007-03-22 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
JP2009528027A (ja) 2006-02-15 2009-08-06 コーリー ファーマシューティカル ゲーエムベーハー オリゴヌクレオチドの処方に関する組成物および方法
JP2012526132A (ja) 2009-05-05 2012-10-25 ミラゲン セラピューティクス 親油性ポリヌクレオチド接合体

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719028A (en) * 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
IL148844A0 (en) * 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
KR100359753B1 (ko) * 1999-12-21 2002-11-09 주식회사 제넥신 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체
AU2001276371A1 (en) 2000-06-30 2002-01-14 Epigenomics Ag Method and nucleic acids for analysing the methylation of genes implicated pharmacogenomics
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
JP4874801B2 (ja) * 2003-06-11 2012-02-15 イデラ ファーマシューティカルズ インコーポレイテッド 安定化免疫調節オリゴヌクレオチド
NZ546275A (en) * 2003-10-30 2009-05-31 Coley Pharm Gmbh C-class oligonucleotides analogs with enhanced immunostimulatory potency
CA2543072A1 (en) * 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
CN1250737C (zh) * 2003-11-07 2006-04-12 深圳市未来海洋科技发展有限公司 含CpG DNA畜禽疫苗佐剂的PCR制备方法
KR100558851B1 (ko) * 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
AU2005247341B2 (en) * 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
WO2006091915A2 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP1764108A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
US8114636B2 (en) * 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
CN100418583C (zh) 2006-02-21 2008-09-17 朱鸿飞 预防和治疗乳腺炎的药物组合物
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
CN102851295B (zh) * 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll 样受体调节性寡核苷酸及其用途
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
KR20100045508A (ko) 2007-08-13 2010-05-03 콜리 파마슈티칼 게엠베하 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프
CA2761736C (en) 2009-05-14 2017-09-26 Bayer Animal Health Gmbh Enhanced immune response in avian species
HRP20181039T1 (hr) 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
CN101979542B (zh) * 2010-10-28 2011-12-28 国家兽用生物制品工程技术研究中心 含CpG基序的核酸序列的制备方法及应用
SI2654785T1 (sl) * 2010-12-22 2019-06-28 Bayer Intellectual Property Gmbh Ojačan imunski odziv pri govejih vrstah
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
JP5872684B2 (ja) * 2011-05-26 2016-03-01 インターベット インターナショナル ベー． フェー． 免疫刺激性オリゴデオキシヌクレオチド
US9315814B2 (en) * 2011-05-26 2016-04-19 Intervet Inc. Immunostimulatory oligodeoxynucleotides
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
AR091569A1 (es) 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
CA2892490A1 (en) 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
EP2992096B1 (en) 2013-05-01 2021-03-03 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
TWI535451B (zh) * 2013-07-19 2016-06-01 財團法人國家衛生研究院 CpG寡去氧核苷酸、包含其之免疫組合物及組合物用於製備治療以刺激免疫反應的藥物之用途
AR097029A1 (es) 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
GB2517700A (en) * 2013-08-27 2015-03-04 Lgc Ltd Oligonucleotides comprising a secondary structure and uses thereof
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
WO2017139570A1 (en) 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506790A (ja) 2003-09-25 2007-03-22 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
JP2009528027A (ja) 2006-02-15 2009-08-06 コーリー ファーマシューティカル ゲーエムベーハー オリゴヌクレオチドの処方に関する組成物および方法
JP2012526132A (ja) 2009-05-05 2012-10-25 ミラゲン セラピューティクス 親油性ポリヌクレオチド接合体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Med. Chem. Lett., 2015, Vol.6, pp.117-122
株式会社 日本遺伝子研究所, "スペーサー修飾オリゴ ＤＮＡ", [online], 2017.09.23, [2022.11.28検索]

Also Published As

Publication number Publication date
PE20200933A1 (es) 2020-09-17
SG11202004773SA (en) 2020-06-29
US11932857B2 (en) 2024-03-19
WO2019115386A9 (en) 2020-07-23
CA3085575A1 (en) 2019-06-20
ZA202004317B (en) 2023-05-31
RU2020122545A3 (enExample) 2022-05-04
US20250215439A1 (en) 2025-07-03
EP3701032A1 (en) 2020-09-02
DOP2020000113A (es) 2020-08-31
TWI821224B (zh) 2023-11-11
ES3052969T3 (en) 2026-01-16
JP7273040B2 (ja) 2023-05-12
JP7760560B2 (ja) 2025-10-27
WO2019115386A1 (en) 2019-06-20
AU2018385257A1 (en) 2020-06-18
MX2020006246A (es) 2020-09-03
MX2025007909A (es) 2025-08-01
TWI911138B (zh) 2026-01-11
TW201936923A (zh) 2019-09-16
IL275217A (en) 2020-07-30
JP2023153970A (ja) 2023-10-18
CO2020007102A2 (es) 2020-06-19
BR112020011845A2 (pt) 2020-11-24
CN111801116A (zh) 2020-10-20
CA3085657A1 (en) 2019-06-20
PH12020550906A1 (en) 2021-05-17
KR102787688B1 (ko) 2025-03-27
AU2018385256B2 (en) 2025-09-25
EP4647437A2 (en) 2025-11-12
TW201936924A (zh) 2019-09-16
KR20200098638A (ko) 2020-08-20
CN111447949A (zh) 2020-07-24
RU2020122553A (ru) 2022-01-17
DOP2020000107A (es) 2020-08-31
CR20200260A (es) 2020-08-01
CN111447949B (zh) 2025-07-11
CN119656298A (zh) 2025-03-21
UY38014A (es) 2019-06-28
CL2020001562A1 (es) 2020-11-06
BR112020011838A2 (pt) 2020-11-24
DK3700564T3 (da) 2025-11-10
TWI900461B (zh) 2025-10-11
RU2020122545A (ru) 2022-01-19
PH12020550903A1 (en) 2021-05-17
CL2020001560A1 (es) 2020-11-06
KR20250048594A (ko) 2025-04-09
US20210062192A1 (en) 2021-03-04
PE20210636A1 (es) 2021-03-23
UY38016A (es) 2019-06-28
EP3700564B1 (en) 2025-09-17
BR112020011815A2 (pt) 2020-11-17
AU2018385256A1 (en) 2020-06-11
AU2018382419B2 (en) 2025-04-10
AU2025205082A1 (en) 2025-07-31
EP3700564A1 (en) 2020-09-02
CL2020001561A1 (es) 2020-11-06
KR20200099556A (ko) 2020-08-24
US20230332162A1 (en) 2023-10-19
KR20200098637A (ko) 2020-08-20
MX2020006244A (es) 2020-09-03
US20210170020A1 (en) 2021-06-10
PL3700564T3 (pl) 2026-02-23
JP2021506779A (ja) 2021-02-22
WO2019115385A1 (en) 2019-06-20
CN120519464A (zh) 2025-08-22
PH12020550904A1 (en) 2021-05-17
JP2023156485A (ja) 2023-10-24
US11542507B2 (en) 2023-01-03
CN111801116B (zh) 2024-11-26
IL274975A (en) 2020-07-30
US20200385733A1 (en) 2020-12-10
PE20210635A1 (es) 2021-03-23
AU2025204678A1 (en) 2025-07-17
AU2018382419A1 (en) 2020-06-04
UY38015A (es) 2019-06-28
US20230174990A1 (en) 2023-06-08
SG11202004952UA (en) 2020-06-29
US12305173B2 (en) 2025-05-20
JP7458977B2 (ja) 2024-04-01
EP4647437A3 (en) 2026-02-18
WO2019115402A1 (en) 2019-06-20
MX2020006243A (es) 2020-09-03
SG11202004471RA (en) 2020-06-29
CO2020007120A2 (es) 2020-06-19
US20240076681A1 (en) 2024-03-07
CN111801419A (zh) 2020-10-20
CO2020007100A2 (es) 2020-06-19
EP3694549A1 (en) 2020-08-19
CA3085661A1 (en) 2019-06-20
DOP2020000106A (es) 2020-08-31
JP2021506246A (ja) 2021-02-22
AU2018385257B2 (en) 2025-04-10
IL275086A (en) 2020-07-30
JP2021506245A (ja) 2021-02-22
TW201940192A (zh) 2019-10-16

Similar Documents

Publication Publication Date Title
KR102787688B1 (ko) 면역자극성 올리고뉴클레오티드
Tursi et al. Bacterial amyloid curli acts as a carrier for DNA to elicit an autoimmune response via TLR2 and TLR9
Krieg Now I know my CpGs
Hashimoto et al. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus
CN1604795B (zh) 具有提高的活性的组合基序免疫刺激寡肽
JP3976742B2 (ja) インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
Fujita et al. Overview and outlook of Toll-like receptor ligand–antigen conjugate vaccines
US20160194642A1 (en) Spherical nucleic acid-based constructs as immunoregulatory agents
US20170175121A1 (en) Self assembling nucleic acid nanostructures
Gunawardana et al. Protection of neonatal broiler chickens following in ovo delivery of oligodeoxynucleotides containing CpG motifs (CpG-ODN) formulated with carbon nanotubes or liposomes
CN101541965A (zh) Tlr配体与抗病毒剂的组合物
JP2010150280A5 (enExample)
PT1511845E (pt) Oligonucleótidos imuno-estimuladores e suas utilizações
EP4114459A1 (en) Coronavirus vaccines comprising a tlr9 agonist
Baek et al. A novel function of phosphorothioate oligodeoxynucleotides as chemoattractants for primary macrophages
CN117050986A (zh) 具有免疫刺激活性的CpG寡聚核苷酸及其用途
Adamsson et al. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin
Fasciano et al. Intervention of Toll-like receptor-mediated human innate immunity and inflammation by synthetic compounds and naturally occurring products
RU2790233C2 (ru) Иммуностимулирующие олигонуклеотиды
Marshall et al. Polymyxin B enhances ISS-mediated immune responses across multiple species
Wu et al. In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model
Coffey et al. Therapeutic targeting of the innate immune system in domestic animals
HK40033950A (en) Immunostimulatory oligonucleotides
Park et al. The production and immunostimulatory activity of double-stranded CpG-DNA
Rees et al. Nonspecific Immunomodulator Therapy: CpG

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230814

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251105

R150 Certificate of patent or registration of utility model

Ref document number: 7770769

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150